Myriad Genetics Receives First Reimbursement Decision for myChoice® Diagnostic System in Japan, Enabling Women with Ovarian Cancer to Benefit from Treatment wi
Font : A-A+ SALT LAKE CITY, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced today that it received its first reimbursement decision for the Myriad myChoice ® Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula ® (niraparib). myChoice was approved by Japans Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication and the reimbursement decision is now in effect. Myriads myChoice test is th...
Source: medindia.net